8-K: Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics has been granted Orphan Drug Designation by the FDA for its CAN-2409 therapy for the treatment of pancreatic cancer.

Summary

• Candel Therapeutics announced that the FDA has granted Orphan Drug Designation to CAN-2409 for the treatment of pancreatic cancer.
• CAN-2409 is a multimodal biological immunotherapy candidate.
• A phase 2 clinical trial showed that CAN-2409, when added to standard of care, more than doubled the median overall survival compared to standard of care alone.
• The estimated median overall survival was 28.8 months with CAN-2409 versus 12.5 months in the control group.
• At 24 months, the survival rate was 71.4% in the CAN-2409 group versus 16.7% in the control group.
• At 36 months, the estimated survival was 47.6% in the CAN-2409 group versus 16.7% in the control group.
• CAN-2409 has also been granted Fast Track Designation by the FDA for pancreatic cancer.
• Orphan Drug Designation provides financial incentives and potential for up to seven years of marketing exclusivity.
• CAN-2409 is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient's tumor and induce an anti-tumor immune response.
• More than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile.

Sentiment

Score: 8

Explanation: The document is very positive due to the FDA Orphan Drug Designation and the significant improvement in survival rates shown in the clinical trial. The company is making good progress in a difficult area of cancer treatment.

Positives

• The FDA's Orphan Drug Designation for CAN-2409 provides financial incentives and potential market exclusivity.
• Clinical trial data shows a significant improvement in median overall survival with CAN-2409 compared to standard of care.
• The treatment has demonstrated a favorable tolerability profile with no significant safety concerns.
• CAN-2409 has shown encouraging monotherapy and combination therapy activity in preclinical and clinical settings.
• The treatment has been administered to over 1,000 patients with a favorable tolerability profile.

Risks

• The company's ability to continue as a going concern is a risk.
• Final data from clinical trials may differ materially from reported interim data.
• There are risks associated with obtaining and maintaining regulatory approval of product candidates.
• The company faces risks related to maintaining its intellectual property.
• The company's business model and strategic plans may not be successfully implemented.

Future Outlook

The company anticipates further development of CAN-2409 and expects to read out clinical trial results in non-small cell lung cancer later in the current quarter. They also expect to continue to develop CAN-2409 for pancreatic cancer.

Management Comments

• Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel, stated that CAN-2409 more than doubled the median overall survival when added to standard of care.
• Garrett Nichols, M.D., M.S., Chief Medical Officer at Candel, mentioned that the Orphan Drug Designation supports Candel's efforts in developing medicines for challenging-to-treat cancers.

Industry Context

The announcement is significant as pancreatic cancer is a highly lethal disease with limited treatment options. The Orphan Drug Designation and positive clinical trial results for CAN-2409 position Candel as a potential leader in this space. The company is also developing treatments for other difficult-to-treat cancers such as non-small cell lung cancer.

Comparison to Industry Standards

• The median overall survival of 28.8 months with CAN-2409 is a significant improvement compared to the 12.5 months in the control group, which is a standard of care.
• Standard treatments for pancreatic cancer, including surgery and chemotherapy, have shown limited success in improving long-term survival rates.
• The 71.4% survival rate at 24 months in the CAN-2409 group is notably higher than the 16.7% in the control group, indicating a substantial improvement in patient outcomes.
• The 47.6% survival rate at 36 months in the CAN-2409 group is also significantly higher than the 16.7% in the control group, suggesting a potential for long-term benefit.
• These results compare favorably to other experimental therapies in pancreatic cancer, where improvements in survival are often modest.

Stakeholder Impact

• Shareholders may view this news positively due to the potential for increased value.
• Patients with pancreatic cancer may benefit from a new treatment option.
• Employees may be motivated by the progress of the company's research.
• The company's reputation may be enhanced by the FDA designation and positive clinical results.

Next Steps

• Candel will continue to develop CAN-2409 for pancreatic cancer.
• The company will read out clinical trial results in non-small cell lung cancer later in the current quarter.
• Candel will continue to evaluate the effects of treatment with CAN-2409 in non-small cell lung cancer, borderline resectable PDAC, and localized, non-metastatic prostate cancer.

Key Dates

Keywords

Orphan Drug Designation, CAN-2409, Pancreatic Cancer, Immunotherapy, FDA, Clinical Trial, Survival Rate, Fast Track Designation, Adenovirus, HSV-tk